Browsing by Author "Akinci M."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Advanced oxidation protein products, ferrous oxidation in xylenol orange, and malondialdehyde levels in thyroid cancer
    (2007) Kosova F.; Çetin B.; Akinci M.; Aslan S.; Ari Z.; Sepici A.; Altan N.; Çetin A.
    Aims and Background: The oxidation of protein plays an essential role in the pathogenesis of an important number of degenerative and cancer diseases, which is now widely recognized. The aim is to examine advanced oxidation protein products (AOPPs), lipid peroxidation products malondialdehyde (MDA), and ferrous oxidation in xylenol orange (FOX) in blood samples of papillary thyroid cancer patients compared with healthy controls to determine the oxidation status and the change after thyroidectomy. Methods: Thirty-five female thyroid cancer patients who underwent total thyroidectomy and 39 female control subjects were included into this study. Prethyroidectomy and postthyroidectomy, AOPP, FOX, and MDA levels were studied. Results: Prethyroidectomy AOPP, FOX, and MDA levels were significantly higher compared to control (P < .05). In postthyroidectomy AOPP, FOX, and MDA levels were significantly decreased compared with prethyroidectomy levels (P < .05). However, postthyroidectomy levels on the 20th day were still significantly higher, compared to control subjects (P < .05). Conclusion: In conclusion, all of AOPP, FOX, and MDA levels that are markers of protein oxidation and lipid hyperoxidation may induce thyroid cancer development and begin to decrease after thyroidectomy. © 2007 Society of Surgical Oncology.
  • No Thumbnail Available
    Item
    Oxidant/antioxidant balance in patients with thyroid cancer
    (2008) Akinci M.; Kosova F.; Çetin B.; Sepici A.; Altan N.; Aslan S.; Çetin A.
    Purpose: To compare the antioxidant enzyme activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and the levels of lipid peroxidation product malondialdehyde (MDA) in blood samples of thyroid cancer patients compared to healthy controls. Methods: 43 control subjects (mean age 44±13 years) and 43 patients (43±13 years) presented with multinodular goiter whose fine needle aspiration revealed malignant cytology were included into this study. The SOD, MDA and GSH-Px activities were measured in control subjects, and before/20 days after thyroidectomy in thyroid cancer patients. Results: SOD activities of pre-thyroidectomy, post-thyroidectomy and control groups were not different (p<0.05). Before thyroidectomy GSH-Px activities were lower (p<0.05) and MDA levels were higher (p<0.05) than the control group. In post- thyroidectomy, GSH-Px activity (p<0.05) increased, and MDA levels (p<0.05) decreased compared to prethyroidectomy levels. After thyroidectomy GSH-Px activity was significantly higher than the control group (p<0.05). Although post-thyroidectomy MDA levels significantly decreased, they were still higher than the control group (p<0.05). Conclusion: The superoxide dismutase does not seem to change with thyroid cancer and thyroidectomy but both antioxidant glutathione peroxidase and lipid peroxidation product malondialdehyde do. These preliminary findings may point out oxidant/antioxidant imbalance associated with thyroid cancer.
  • No Thumbnail Available
    Item
    Leptin levels in thyroid cancer
    (Elsevier (Singapore) Pte Ltd, 2009) Akinci M.; Kosova F.; Cetin B.; Aslan S.; Ari Z.; Cetin A.
    BACKGROUND: Leptin has physiological roles in multiple systems, and has possible effects on several carcinogenesis steps. The aim of this study was to investigate the leptin levels in thyroid papillary carcinoma (TPC) patients. METHODS: Forty-three female TPC patients and 30 healthy female control subjects were recruited for the study. TPC was diagnosed by fine needle aspiration biopsy. TPC patients had a bilateral total thyroidectomy operation and their leptin levels were measured before and 20 days after the operation. RESULTS: Serum leptin levels of TPC patients were higher than in control group subjects (21.15 ± 14.12 ng/mL vs. 9.89 ±0.21 ng/mL, p< 0.05). The leptin levels decreased after total thyroidectomy (13.92 ± 10.55 ng/mL) compared to prethyroidectomy levels (22.94 ± 14.67 ng/mL) in 34 patients who came to the follow-up visit (p< 0.05). However, the decreased post-thyroidectomy levels of leptin were still statistically significantly higher than the control group levels. Multivariate regression analysis showed that the leptin levels in TPC patients were not related to age, menopausal status or pathologic occult status but were directly related to the cancer group. CONCLUSION: Leptin levels were elevated in thyroid cancer, decreased after total thyroidectomy, and might be associated with thyroid papillary carcinogenesis. © 2009 Elsevier. All rights reserved.
  • No Thumbnail Available
    Item
    Serum copper levels in benign and malignant thyroid diseases
    (2012) Kosova F.; Cetin B.; Akinci M.; Aslan S.; Seki A.; Pirhan Y.; Ari Z.
    Objective: To examine the changes in serum copper (Cu) levels in benign and malignant thyroid disease in humans. Background: Thyroid hormones influence the metabolism of trace elements including copper. Methods: 47 papillary thyroid cancer and 43 benign multinodular goitre patients who underwent total thyroidectomy and 37 healthy control subjects were included into this study. All of the patients and controls were females. Serum Cu levels were detected with atomic absorption spectrophotometer. Results: In the papillary thyroid cancer group serum level of Cu was 131.61±33.9 μg/dL before surgery and 120.81±30.4 μg/dL after 20 days from surgery. In the benign group serum Cu level was 84.75±12.1 μg/dL and 68.01±9.4 μg/dL postoperatively. These results were compared to healthy control's value of 105.87±10.68 μg/dL. In the papillary thyroid cancer group pre- and postoperative serum Cu level was significantly higher when compared to control group (p<0.05). Postoperative serum Cu level significantly decreased when compared to pre-operative level(p<0.05), in which, it was still higher than the control(p<0.05). In the benign group pre- and postoperative serum Cu level was significantly lower than in the control group (p<0.05). Postoperative serum Cu level significantly decreased when compared to pre-operative level in the benign group (p<0.05). Conclusion: This is a pioneer study to examine serum Cu level in benign and malignant thyroid patients compared to controls. In our small groups serum Cu levels increased in malignant thyroid patients and decreased in the benign group.